Alvotech, Kashiv BioSciences enter licensing agreement for proposed Xolair biosimilar
Xolair, which contains omalizumab, is indicated for diseases such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria.